STOCK TITAN

ImmunoGen, Inc. - IMGN STOCK NEWS

Welcome to our dedicated news page for ImmunoGen (Ticker: IMGN), a resource for investors and traders seeking the latest updates and insights on ImmunoGen.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ImmunoGen's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ImmunoGen's position in the market.

Rhea-AI Summary
ImmunoGen's Marketing Authorization Application for mirvetuximab soravtansine accepted by the EMA for the treatment of platinum-resistant ovarian cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.42%
Tags
none
-
Rhea-AI Summary
ImmunoGen Inc. to host conference call to discuss third quarter 2023 operating results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.08%
Tags
-
Rhea-AI Summary
ImmunoGen approves grants of stock options and RSUs to new employees under the Inducement Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
ImmunoGen Inc. announces findings from Phase 3 trial of ELAHERE in patients with FRα-positive platinum-resistant ovarian cancer, showing improvements in progression-free survival, objective response rates, and overall survival compared to chemotherapy. The benefit seen with ELAHERE in patients treated with a prior PARP inhibitor is particularly encouraging. ELAHERE demonstrates a tolerable safety profile. The company plans to submit applications to regulatory authorities for approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.9%
Tags
none
-
Rhea-AI Summary
ImmunoGen grants non-qualified stock options and restricted stock units to new CFO Lauren White
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.25%
Tags
none
-
Rhea-AI Summary
ImmunoGen appoints Lauren White as Senior Vice President and Chief Financial Officer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.06%
Tags
management
Rhea-AI Summary
ImmunoGen, Inc. approves grants of stock options and RSUs to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
none
-
Rhea-AI Summary
ImmunoGen enters exclusive collaboration with Takeda to develop and commercialize ELAHERE in Japan, receiving $34 million upfront and milestone payments, as well as double-digit royalties on future net sales in Japan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.66%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.92%
Tags
none
Rhea-AI Summary
IMGN: ImmunoGen Announces Departure of Chief Medical Officer and Successor Appointment. Anna Berkenblit, MD, Senior Vice President and Chief Medical Officer, is stepping down to pursue new opportunities outside of ImmunoGen. Michael Vasconcelles, MD, Executive Vice President, Research, Development, and Medical Affairs, will assume the role of Chief Medical Officer. The announcement highlights Dr. Berkenblit's significant contributions to ImmunoGen's pivotal development program for ELAHERE (mirvetuximab soravtansine-gynx) and the accelerated approval for patients with platinum-resistant ovarian cancer. The press release also emphasizes the company's continued advancement of their clinical pipeline of next-generation ADCs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.71%
Tags
none
ImmunoGen, Inc.

Nasdaq:IMGN

IMGN Rankings

IMGN Stock Data

8.72B
247.85M
0.32%
86.52%
7.38%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Boston

About IMGN

immunogen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics with its proprietary antibody-drug conjugate (adc) technology. the company's lead product candidate, mirvetuximab soravtansine, is a potential treatment for folate receptor α-positive ovarian cancers and other solid tumors. leading healthcare companies have licensed rights to use immunogen's technology to develop novel anticancer therapies, and roche's marketed product, kadcyla, utilizes immunogen's adc technology. more information about the company can be found at www.immunogen.com.